143 related articles for article (PubMed ID: 29334312)
1. Targeting of phospho-eIF4E by homoharringtonine eradicates a distinct subset of human acute myeloid leukemia.
Zhou H; Xu RZ; Gu Y; Shi PF; Qian S
Leuk Lymphoma; 2020 May; 61(5):1084-1096. PubMed ID: 29334312
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule induction of phospho-eIF4E sumoylation and degradation via targeting its phosphorylated serine 209 residue.
Gu Y; Zhou H; Gan Y; Zhang J; Chen J; Gan X; Li H; Zheng W; Meng Z; Ma X; Wang X; Xu X; Xu G; Lu X; Liang Y; Zhang X; Lu X; Huang W; Xu R
Oncotarget; 2015 Jun; 6(17):15111-21. PubMed ID: 25915158
[TBL] [Abstract][Full Text] [Related]
3. Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia.
Wei W; Huang S; Ling Q; Mao S; Qian Y; Ye W; Li F; Pan J; Lin X; Huang J; Huang X; Zhai Y; Sun J; Jin J
J Transl Med; 2022 Jul; 20(1):299. PubMed ID: 35794605
[TBL] [Abstract][Full Text] [Related]
4. Homoharringtonine synergy with oridonin in treatment of t(8; 21) acute myeloid leukemia.
Zhang W; Lu Y; Zhen T; Chen X; Zhang M; Liu P; Weng X; Chen B; Wang Y
Front Med; 2019 Jun; 13(3):388-397. PubMed ID: 30206768
[TBL] [Abstract][Full Text] [Related]
5. Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms.
Tan M; Zhang Q; Yuan X; Chen Y; Wu Y
J Exp Clin Cancer Res; 2019 Jul; 38(1):308. PubMed ID: 31307525
[TBL] [Abstract][Full Text] [Related]
6. The eukaryotic translation initiation factor eIF4E is a direct transcriptional target of NF-κB and is aberrantly regulated in acute myeloid leukemia.
Hariri F; Arguello M; Volpon L; Culjkovic-Kraljacic B; Nielsen TH; Hiscott J; Mann KK; Borden KL
Leukemia; 2013 Oct; 27(10):2047-55. PubMed ID: 23467026
[TBL] [Abstract][Full Text] [Related]
7. Homoharringtonine potentiates the antileukemic activity of arsenic trioxide against acute myeloid leukemia cells.
Chen P; Zhan W; Wang B; You P; Jin Q; Hou D; Wang X; You R; Zou H; Chen Y; Huang H
Exp Cell Res; 2019 Mar; 376(2):114-123. PubMed ID: 30763586
[TBL] [Abstract][Full Text] [Related]
8. Homoharringtonine targets Smad3 and TGF-β pathway to inhibit the proliferation of acute myeloid leukemia cells.
Chen J; Mu Q; Li X; Yin X; Yu M; Jin J; Li C; Zhou Y; Zhou J; Suo S; Lu D; Jin J
Oncotarget; 2017 Jun; 8(25):40318-40326. PubMed ID: 28454099
[TBL] [Abstract][Full Text] [Related]
9. Abivertinib, a novel BTK inhibitor: Anti-Leukemia effects and synergistic efficacy with homoharringtonine in acute myeloid leukemia.
Huang S; Pan J; Jin J; Li C; Li X; Huang J; Huang X; Yan X; Li F; Yu M; Hu C; Jin J; Xu Y; Ling Q; Ye W; Wang Y; Jin J
Cancer Lett; 2019 Oct; 461():132-143. PubMed ID: 31310800
[TBL] [Abstract][Full Text] [Related]
10. Azacitidine Is Synergistically Lethal with XPO1 Inhibitor Selinexor in Acute Myeloid Leukemia by Targeting XPO1/eIF4E/c-MYC Signaling.
Long H; Hou Y; Li J; Song C; Ge Z
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047788
[TBL] [Abstract][Full Text] [Related]
11. MAP4K1 functions as a tumor promotor and drug mediator for AML via modulation of DNA damage/repair system and MAPK pathway.
Ling Q; Li F; Zhang X; Mao S; Lin X; Pan J; Ye W; Wei W; Qian Y; Hu C; Huang X; Wang J; Wang H; Huang J; Wang Y; Jin J
EBioMedicine; 2021 Jul; 69():103441. PubMed ID: 34166980
[TBL] [Abstract][Full Text] [Related]
12. Phospho-eIF4E: A New Target for Acute Myeloid Leukemia.
Jia X; Zhou H
Curr Protein Pept Sci; 2021 Oct; 22(4):328-335. PubMed ID: 33605855
[TBL] [Abstract][Full Text] [Related]
13. The antileukemia roles of PP242 alone or in combination with daunorubicin in acute leukemia.
Shi F; Yang X; Gong Y; Shi R; Yang X; Naren D; Wu J
Anticancer Drugs; 2015 Apr; 26(4):410-21. PubMed ID: 25535978
[TBL] [Abstract][Full Text] [Related]
14. [Synergistic effect of azacitidine with homoharringtonine by activating the c-MYC/DDIT3/PUMA axis in acute myeloid leukemia].
Li J; Huang YQ; Zi J; Song CH; Ge Z
Zhonghua Xue Ye Xue Za Zhi; 2023 Dec; 44(12):1001-1009. PubMed ID: 38503523
[No Abstract] [Full Text] [Related]
15. The efficacy and safety of a homoharringtonine-based protocol for children with acute myeloid leukemia: A retrospective study in China.
Tang Y; Luo C; Shen S; Xue H; Pan C; Hu W; Chen X; Cai J; Chen J; Tang J
Pediatr Hematol Oncol; 2021 Mar; 38(2):97-107. PubMed ID: 33016804
[TBL] [Abstract][Full Text] [Related]
16. Dihydropyrimidinase-like 2 can serve as a novel therapeutic target and prognostic biomarker in acute myeloid leukemia.
Li F; Ling Q; Lian J; Chen Y; Hu C; Yang M; Zhang X; Li C; Mao S; Ye W; Li X; Lin X; Wei W; Huang X; Pan J; Qian Y; Wang J; Lu Y; Jin J
Cancer Med; 2023 Apr; 12(7):8319-8330. PubMed ID: 36621846
[TBL] [Abstract][Full Text] [Related]
17. [Expression of eIF4E in patients with leukemia and its clinical significance].
Zhu LF; Chen XJ; Hu JD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):1-6. PubMed ID: 23484680
[TBL] [Abstract][Full Text] [Related]
18. Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms.
Yuan F; Li D; Li G; Cheng C; Wei X
Ann Transl Med; 2022 Apr; 10(8):490. PubMed ID: 35571387
[TBL] [Abstract][Full Text] [Related]
19. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin.
Assouline S; Culjkovic B; Cocolakis E; Rousseau C; Beslu N; Amri A; Caplan S; Leber B; Roy DC; Miller WH; Borden KL
Blood; 2009 Jul; 114(2):257-60. PubMed ID: 19433856
[TBL] [Abstract][Full Text] [Related]
20. Homoharringtonine deregulates
Chen XJ; Zhang WN; Chen B; Xi WD; Lu Y; Huang JY; Wang YY; Long J; Wu SF; Zhang YX; Wang S; Li SX; Yin T; Lu M; Xi XD; Li JM; Wang KK; Chen Z; Chen SJ
Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2220-2225. PubMed ID: 30659143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]